Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention—MACUSTAR
Abstract Background There is an unmet need for treatment options in intermediate age-related macular degeneration (iAMD). However, for any new interventions to be tested in clinical trials, novel currently unavailable clinical endpoints need to be developed. Thus, the MACUSTAR study aims to develop...
Main Authors: | Jan H. Terheyden, Frank G. Holz, Steffen Schmitz-Valckenberg, Anna Lüning, Matthias Schmid, Gary S. Rubin, Hannah Dunbar, Adnan Tufail, David P. Crabb, Alison Binns, Clara I. Sánchez, Carel Hoyng, Philippe Margaron, Nadia Zakaria, Mary Durbin, Ulrich Luhmann, Parisa Zamiri, José Cunha-Vaz, Cecília Martinho, Sergio Leal, Robert P. Finger, on behalf of the MACUSTAR consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04595-6 |
Similar Items
-
When do we need clinical endpoint adjudication in clinical trials?
by: Claes Held
Published: (2019-01-01) -
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
by: Hideki Maeda, et al.
Published: (2021-06-01) -
Patients’ preferences for selection of endpoints in cardiovascular clinical trials
by: Robert D. Chow, et al.
Published: (2014-02-01) -
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)
by: Jorrit Tjeertes, et al.
Published: (2023-07-01) -
Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
by: Kexin Ling, et al.
Published: (2022-11-01)